Use Of Dulaglutide And Sitagliptin On The Management Of...

This article discusses the use of dulaglutide and sitagliptin in the management of type 2 diabetes. Dulaglutide is a recombinant GLP-1 Fc fusion protein, which acts by linking GLP-1 analog peptide and a variant of lgG4 Fc fragments in humans. As such, the analog of GLP-1 has posed effects and has shown elevated efficacies in the management of type 2 diabetes. The primary efficacy in the baseline of HbA was altered during the end of 52nd week. The objective of secondary efficacy included a change in HbA during the end of the 26th and 104th week. The percentage of patients achieved HbA targets ranged between 7.5% to 6.5% in a central laboratory and the body changed significantly. However, current treatment majorly focuses on increasing†¦show more content†¦Type 2 diabetes is an increasingly common endocrine disorder. Therefore, it is characterized by chronic hyperglycemia and results in multiple tissue compartments that include microvascular and macrovascular implications. Thi s article discusses subcutaneous dulaglutide, leading to its approval for type 2 diabetes. Dulaglutide is a recombinant GLP-1 Fc fusion protein that links human GLP-1 analog peptide and a variant of human lgG4 Fc fragment. Thus, an analog of GLP-1 has developed long lasting effects and has proven to be effective in type 2 diabetes. It offers greater convenience to the patient. It consists of DPP-IV that protects GLP-1 analog which is covalently linked to human heavy chain by a small peptide linker. The mechanism of action of dulaglutide involves activation of GLP-1 receptor; a membrane-bound cell surface receptor coupled to adenyl cyclase in ÃŽ ² cells. Increase in intracellular cells leads to a glucose-dependent release of insulin. Reduction in the secretion of glucagon and slow gastric emptying is done by Dulaglutide (K). Continued administration of dulaglutide increases fasting insulin and C-peptide concentrations, thus reducing fasting glucagon concentrations. Healthy patients as well as adults with type 2 diabetes have similar dulaglutide pharmacokinetics. It occurs slowly, but is well absorbed into the systemic circulation, thus reaching a maximum plasma concentration. Despite the fact that treatment of diabetes